EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer
Author:
Affiliation:
1. The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
2. Jyoban Hospital of Tokiwa Foundation, Fukushima, Japan
Publisher
American Medical Association (AMA)
Subject
Oncology,Cancer Research
Reference8 articles.
1. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.;Kessler;JAMA,1993
2. Limitations and strengths of spontaneous reports data.;Goldman;Clin Ther,1998
3. Tyrosine kinase inhibitor-induced interstitial lung disease: clinical features, diagnostic challenges, and therapeutic dilemmas.;Shah;Drug Saf,2016
4. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.;Brahmer;N Engl J Med,2015
5. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.;Borghaei;N Engl J Med,2015
Cited by 220 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature;Cancer Treatment Reviews;2024-09
2. Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched‐Pair Cohort Study Using a Nationwide Inpatient Database;Clinical Lung Cancer;2024-09
3. Potential therapeutic option for EGFR-mutant small cell lung cancer transformation: a case report and literature review;Frontiers in Immunology;2024-08-21
4. Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study;Cancer Letters;2024-08
5. Immune Checkpoint Inhibitors in first versus second line of metastatic non-small cell lung cancer: Real-World Overall Survival;Meditsinskiy sovet = Medical Council;2024-07-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3